



FyoniBio Renews CIR Accreditation to Support French R&D Collaborations Through 2028

Press Release

Berlin, Germany — August 2026

FyoniBio, a European biologics Contract Development Organization (CDO) specializing in bioprocess development and bioanalytical services, today announced the three-year renewal of its [Crédit d'Impôt Recherche \(CIR\) accreditation](#) through 2028. This accreditation enables French pharmaceutical and biotech partners to significantly offset their research and development expenses when collaborating with FyoniBio.

The CIR is a French government tax incentive designed to foster scientific innovation and industrial R&D. Under this scheme, eligible French companies partnering with FyoniBio can include FyoniBio's service invoices in their R&D expenditure calculations, qualifying them for tax credits of up to 30%.

"Long-term relationships with the French biopharmaceutical community are very important to us," said Dr. Lars Stöckl, Managing Director of FyoniBio. "Retaining our CIR status means our French clients can continue to rely on us not just as a service provider, but as a accessible, cost-effective partner for their research."

About FyoniBio

FyoniBio is a biologics service provider with over 15 years of scientific expertise and a proven track record of supporting more than 100 biologics projects for biotech and pharma companies worldwide. Trusted by partners whose products have reached clinical development in both FDA and EMA regions, FyoniBio offers a broad service portfolio covering the entire development chain — from cell line and process development to analytical characterization and clinical bioanalysis under GCLP.

Our team combines deep scientific understanding with flexibility and transparent communication to deliver tailored solutions that meet each project's specific needs. All services are performed under our ISO 9001–certified quality management system, ensuring full compliance with international ISO and ICH standards.

Learn more at: <https://www.fyonibio.com/>

Press Contacts

DR. LARS STÖCKL
Managing Director, FyoniBio GmbH
lars.stoeckl@fyonibio.com